SGO Annual Mtg 2023: Miscellaneous topics

This post completes my coverage of the 2023 SGO Annual Meeting. Below are some tweets on  miscellaneous topics from treatments to testing.

 Cryocompression

Prevention of neuropathy in gyn cancer patients. 

The data are in! Cryocompression therapy works during chemo and prevents subjective neuropathy in patients with gyn cancers. Congrats @MKMontesDeOca @LHavrilesky and @dukeobgyn team. #SGOMtg #PatientsPurposeProgress pic.twitter.com/VU6p3JYvMG

— Rebecca Previs (@BeccaPrevisMD) March 25, 2023

 Immune Biomarkers in Locally Advanced Cervical Cancer 

Combo of durvalumab concurrent with radiation produce more tumor-associated T-cells clones. 

Zamarin presenting LACC Evolution of peripheral and tumor immune parameters as biomarkers of differential sequencing of immune checkpoint blockade and chemoradiotherapy in locally advanced cervical cancer: An NRG Oncology/GOG Study #SGOMtg #gyncsm pic.twitter.com/ky1yWh3jjd

— Dee Sparacio (@womenofteal) March 25, 2023

Palliative Care  

Higher value and less aggressive care at end of life with early palliative care.

Impact of Timing of Palliative Care
Initiation on End-of-Life Quality Metrics
and Health Resource Utilization ,Mah #SGOmtg, #gyncsm Early palliative care is assoc w/ higher-value and less aggressive end-of-life care#palliativecare pic.twitter.com/mpPKFZY9ig

— Dee Sparacio (@womenofteal) March 28, 2023

Palliative care referral was impacted by diagnosis and insurance coverage. 

Palliative Care Utilization of Gynecology Oncology Patients with Advanced Cancer #SGOMtg #gyncsm Disparities in palliative care referral based on cancer
diagnosis/insurance were significant,No significant difference in referrals
based on age, race/ethnicity or preferred language pic.twitter.com/11D2SXbxqo

— Dee Sparacio (@womenofteal) March 28, 2023

Breast MRI 

Denials in women with hereditary BRCA1/2 mutations with gyn cancer diagnosis.

Barriers to early detection: Breast MRI denials in patients with
germline BRCA1/2 mutations Gordhandas, #SGOmtg #gyncsm #bcsm #patientspurposeprogress increase time to rec MRI, collaborate w/insurers pic.twitter.com/WfEhy7VwTX

— Dee Sparacio (@womenofteal) March 28, 2023

Funding gaps  

Significant gaps in funding for gyn cancers compared to other cancer types

Significant funding gaps exist for lethal gynecologic cancers compared to other malignancies. We all need to advocate with Congress for more funding! Highlighted by Dr Victor Dzau #NAM during Presidential Lecture at #sgomtg ⁦@uppals⁩ ⁦@SGO_org⁩ pic.twitter.com/gV4AiRB6wl

— Joshua Garrett Cohen (@JCohenMD) March 25, 2023

Obesity  

Japanese study showed obese women have higher risk of uterine cancer

The Consequence of Obesity on the Risk of Uterine Cancer Incidence in Younger vs. Older Adults Stewart #SGOMtg #gyncsm Taiwan data | Obese and overweight patients have a higher risk of uterine cancer pic.twitter.com/473v6Lpu6m

— Dee Sparacio (@womenofteal) March 28, 2023

HPV vaccination

Intervention helps uptake of HPV in clinic 

Every nudge counts: Impact of a clinical intervention bundle on the uptake of HPV vaccination in an under-resourced clinic
Byrne #SGOmtg #gyncsm pic.twitter.com/pkJ5RVWGqW

— Dee Sparacio (@womenofteal) March 28, 2023

 Tremelimumab, durvalumab, and radiotherapy

Patients with cervical or vaginal cancers had good overall response rates if high in PDL1

#SGOMtg #gyncsm
A phase I study of tremelimumab, durvalumab, and hypofractionated radiotherapy for metastatic gynecologic cancers
Lin , 18 patients cervical and vaginal, ORR in PDL1 high patients pic.twitter.com/IMqBpQZOFI

— Dee Sparacio (@womenofteal) March 27, 2023

In June I will report on  research of interest presented at the ASCO annual meeting which I will attend virtually. 

Dee

Every Day is a Blessing!

SGO Annual Mtg 2023 : Disparities/ Equity Research

In this post I will focus on sharing Tweets and information from the Diversity, Equity presentations I attended at the 2023 SGO Annual Meeting. There were a number of important studies presented to better understand equity issues for those diagnosed with a gynecologic cancer. 

Two studies focused on Asian / Pacific Islanders 

Do we need to separate out non-hispanic Pacific Islanders from Asians? 

TY to @sarahleemdmba for bringing #disaggregASIAN to @SGO_org: Asians/#NHPI are not a monolith — not our cancers, comorbidities, or treatments. Building better datasets is a key first step to better pt outcomes! Beautiful work!! @BPothuri pic.twitter.com/bVzEtrwuWm

— Jhalak Dholakia, MD (@dholakiamd) March 28, 2023

Unmasking Disparities in Survival Among Asian American and Pacific Islander Women with Cervical Cancer: A National Cancer Database Analysis From 2004 to 2015 Penalosa #SGOmtg #gyncsm disparities cervical cancer among AAPI women Pacfic Islander patients have worse outcomes pic.twitter.com/YPb0GSBIXv

— Dee Sparacio (@womenofteal) March 26, 2023

Food deserts associated with worse survival outcomes.

Dr. Lugo Santiago, Dr. Mihae Song, and team identify food deserts in California are associated with worse survival for pts with ovarian, cervical, and endometrial cancer. Important work shedding light on this disparity that needs to be addressed @JeffLinMD @COH_GynOncology… pic.twitter.com/pwNlr9mvSX

— Joshua Garrett Cohen (@JCohenMD) March 26, 2023

 Cervical Cancer 

Closing the Racial Disparity Gap in
Cervical Cancer Incidence and Mortality:
The Potential Impact of Screening and
Vaccination -Eakin #SGOmtg #gyncsm multiple data bases used. pic.twitter.com/A7TOghkjPd

— Dee Sparacio (@womenofteal) March 26, 2023

 

Facilitators to cervical cancer screening in a minority, urban, underserved population
Noel Higgason#SGOmtg #gyncsm increase local community involvement to encourage screening pic.twitter.com/AWf8LaV2It

— Dee Sparacio (@womenofteal) March 26, 2023

 

 

Clinical Trials - Comorbidity exclusions

Call to action by DrCarolAghajanian to develop inclusive clinical trial protocols for pts with gynecologic cancer. We need to ensure equitable access for all. Important work by Dr Oluloro and ⁦@KemiDoll⁩ demonstrating existing disparities #gyncsn #sgomtg. ⁦@SGO_org⁩ pic.twitter.com/KeVFtwDjTO

— Joshua Garrett Cohen (@JCohenMD) March 25, 2023

Dr Oluloro highlighting disparities in clinical trial enrollment based on comorbidity based exclusion criteria by race #equity #gyncsm #SGOMtg #sgo2023 pic.twitter.com/bq8KEC5USJ

— Nicole D. Fleming MD (@nicoleflemingmd) March 25, 2023

#SGOMtg Richardson Underrepresentation of Non-White Enrollment in Gynecologic Oncology: An analysis of over 350 Clinical Trials significant under enrollment of ethnic minority groups #gyncsm pic.twitter.com/lcl1lfLzLj

— Dee Sparacio (@womenofteal) March 25, 2023

Geographic disparities in access to gynecologic oncologists

Kudos Dr Desravines on an outstanding ⁦@SGO_org⁩ plenary! Despite doubling of GYNONC workforce in last 20 yrs, cancer care geographic disparities for rural & URM populations remain high. It’s high time for solutions to close this gap! #patientspurposeprogress #sgo23AM pic.twitter.com/oVPrzaosJe

— Amanda Nickles Fader, MD (@amandanfader) March 25, 2023

Desravines discussing geographic access to care of women by gyn oncs #SGOMtg pic.twitter.com/aZ0CZKhPnz

— Dee Sparacio (@womenofteal) March 25, 2023

 Health Literacy 

Low income and racial/ ethnic minorities had lower rates of health literacy which impacts health outcomes  

Additional information may be found at  https://www.healio.com/news/hematology-oncology/20230329/1-in-4-patients-at-gynecologic-oncology-clinic-lack-adequate-cancer-health-literacy

 

Caring for transgender patients

Care of the Transgender patient: Cancer related concerns Rimel#SGOmtg #gyncsm Important discussion on cancer screening and care. pic.twitter.com/x0CyUQ1AWj

— Dee Sparacio (@womenofteal) March 27, 2023

 Please visit Welcoming Spaces at https://www.sgo.org/welcomingspaces/ for more information. 

Tomorrow's post will highlight some other sessions of interest from palliative care, to compression therapy to  biomarkers to funding.  See you tomorrow!

Dee

Every Day is a Blessing! 

SGO Annual Mtg 2023 Highlights : Ovarian Cancer

I've gathered together some interesting Tweets about ovarian cancer research studies from the SGO 2023 Annual Meeting.

Botensilimab An Fc-engineered recombinant human immunoglobulin (Ig) G1 monoclonal antibody and Balstilimab a PD-1 inhibitor 

Botensilimab, BOT, a novel innate/adaptive
immune activator, plus balstilimab
(anti-PD-1) in patients with recurrent
platinum refractory/resistant ovarian cancer, #SGOmtg #gyncsm Bockorny
BOT = CTLA 4 inhibitor, 1st in Human study ,heavily pretreated ORR 33%, pic.twitter.com/7sz5YtLTGa

— Dee Sparacio (@womenofteal) March 27, 2023

Additional information  https://www.cancernetwork.com/view/botensilimab-plus-balstilimab-yields-enduring-responses-in-r-r-ovarian-cancer

 

SOLAR Trial olaparib (Lynparza) with selumetinib (Koselugo) in patients with RAS-mutant gynecologic malignancies

Exciting data from the SOLAR trial presented by ⁦@ShannonWestin⁩ on the use of combination PARPi and MEKi for RAS mutated recurrent ovarian and endometrial cancer! #SGOmtg #oncsurgery ⁦@MDAndersonNews⁩ pic.twitter.com/sxPEFOcDMI

— Aaron Shafer (@aaronshafer99) March 27, 2023

Find additional information at https://www.onclive.com/view/dr-westin-on-outcomes-of-the-solar-trial-in-ras-mutant-gynecological-malignances

SOLO 1 trial results - 7 year overall survival reported

The 7-year results of SOLO1 study have reported!

Amazingly they got a great durable benefits in OS as well as TFST/TSST, which means most of patients who recieved olaparib as maintenance therapy haven't experienced relapse.#SGOMtg pic.twitter.com/lYr6RHz8yl

— Yukio Suzuki (@yetii18) March 26, 2023

Solo-1 7year follow up presented by Cara Matthews @SGO_org annual meeting. Survival benefits confirmed. No new safety signals. #SGOmtg #gyncsm pic.twitter.com/JP0qkEKkwc

— Annie Ellis (@Stigetta) March 26, 2023

Additional information may be found at https://www.onclive.com/view/dr-mathews-on-maintenance-olaparib-in-ovarian-cancer

 

NOVA trial Recurrent ovarian cancer - Niraparib (Zejula) did not produce a statistically significant overall survival (OS) benefit compared with placebo.  

Dr. Ursula Matulonis presents Final OS and Safety for ENGOT-OV16/NOVA. No new safety signals. #SGOmtg #gyncsm pic.twitter.com/kG7gG39gWo

— Annie Ellis (@Stigetta) March 26, 2023

 

Minimally invasive surgery vs open surgery

Impressive results from @KJorgensenMD. Study of NCDB demonstrated improved overall survival w/ minimally invasive surgery as opposed to open interval tumor reductive surgery in advanced #OvarianCancer. The LANCE study will provide prospective data here #SGOMtg #oncsurgery #gyncsm pic.twitter.com/STE3UNz7zc

— Shannon Westin (@ShannonWestin) March 26, 2023

 

Neoadjuvant olaparib - improved surgical outcomes 

After neoadjuvant talazoparib results in BRCAm BC (Litton J.K. 2017), neoadjuvant olaparib in #ovariancancer (with mutation in BRCA1/2, RAD51C/D, or PALB2) by @ShannonWestin shows outstanding surgical outcomes after only 2 cycles of olaparib, even in Stage IV pts #SGOMTG #SGO2023 pic.twitter.com/T4Rdk9pCJ5

— Allegra Rollo (@AllegraRollo) March 25, 2023

 For additional information see https://www.onclive.com/view/neoadjuvant-olaparib-proves-feasible-aids-optimal-resection-in-brca-mutant-ovarian-cancer

mirvetuximab soravtansine-gynx (Elahere)

Learning more about Elahere a monoclonal antibody directed against folate receptor alpha in OC @ImmunoGenInc Industry Sponsored session ~ 35% patients w/ OC express high levels SORAYA trial #SGOMtg #gyncsm pic.twitter.com/y6ThbanbWs

— Dee Sparacio (@womenofteal) March 25, 2023

Steroid eye drops followed by lubricating eye drops and regular visits to an ophthalmologist should be scheduled . For more information see https://www.onclive.com/view/dr-matulonis-on-the-management-of-mirvetuximab-soravtansine-related-toxicities-in-fr-ovarian-cancer

venous thromboembolism (VTE)

Higher Incidence of Venous Thromboembolism Associated with Increasing Lines of Chemotherapy in Heavily Treated Ovarian Cancer Patients
Lampert #SGOMtg #gyncsm single institution, VTE assoc w/ increasked # lines of treatment , > 50% of VTEs required hospitalization pic.twitter.com/DZFgpjzRgI

— Dee Sparacio (@womenofteal) March 28, 2023

 

For additional information see https://www.medpagetoday.com/meetingcoverage/sgo/103793

If you would like to share additional ovarian cancer studies presented at SGO 2023 please mention in the comment section below. Thanks.

Stop by tomorrow to read Tweets that highlighted studies on equity, diversity at the meeting.

 

Dee

Every Day is a Blessing! 

 

SGO Annual Mtg 2023 Highlights: Endometrial Cancer

The Late Breaking Abstracts session at the SGO Annual meeting included two important endometrial cancer studies using immune checkpoint inhibitors.

Dr Eskander presented Pembrolizumab versus Placebo in Addition to Carboplatin and Paclitaxel for Measurable Stage 3 or 4a, Stage 4b or recurrent Endometrial Cancer : Phase 3 NRG GYO18 Study (Keynote 868)

Pembrolizumab is an immune checkpoint inhibitor that binds to the protein PD-1.  Endometrial cancer patients who were stage III, IVa , IVB or recurrent endometrial cancer enrolled in the trial. They were given carboplatin / paclitaxel ( Standard of care) with pembrolizumab, a PD1 inhibitor or placebo followed by maintenance with pembrolizumab. Patients were separated into two cohorts according to whether they had mismatch repair–deficient (dMMR) or mismatch repair–proficient (pMMR) disease. The interim efficacy analysis showed in the pMMR cohort, median progression-free survival was 13.1 months with pembrolizumab and 8.7 months with placebo. 

The study was released minutes after the presentation Sunday afternoon in the NEJM.  https://www.nejm.org/doi/full/10.1056/NEJMoa2302312  Additional information may be found here.

Dr Mirza presented Dostarlimab for Primary Advanced or Recurrent Endometrial Cancer. (Ruby trial)

Dostarlimab, an immune checkpoint inhibitor to anti-programmed cell death receptor-1 (PD-1) was used in this Phase 3 trial. Women  with stage III, IV or recurrent endometrial cancer were give dostarlimab with carboplatin/ paclitaxel and then maintenance dostarlimab every 6 weeks for up to 3 years. In the dMMR–MSI-H ( mismatch repair–deficient, microsatellite instability–high) population, estimated progression-free survival at 24 months was 61.4%  versus 15.7% in the placebo group. Overall survival at 24 months was 71.3% with dostarlimab and 56.0% with placebo.   

This study was also published online in the NEJM shortly after the presentation. nej.md/40lFbBN

Additional information may be read here. 

This tweet sums up the two studies

Such an amazing leap forward in endometrial cancer. Absolutely revolutionary - and such important and mind-blowing results that will impact and help so many of our patients. &an especially emotional standing ovation for our patients and their families #SGOMtg @SGO_org @rne_md pic.twitter.com/N5bK0bPZdx

— Jharna M. Patel, MD (@JharnaMPatel) March 27, 2023

Comments that I heard from various gynecologic oncologists after the session was that these two studies will impact endometrial cancer patient care in the near future.

 More SGO news to come!

 

Dee

Every day is a blessing!